high mobility group nucleosomal binding domain 2 pseudogene 9Genealiases: HMG17L1 · HMGN2L9 · dJ388M5 · dJ388M5.2
Q-omics provides the consensus-scored HMGN2P9 profile across patient tissues and cancer cell-line models. HMGN2P9 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, HMGN2P9 is differentially expressed in 1, with the highest sampling consensus in LUAD. Additionally, HMGN2P9 RNA expression shows 5,742 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight UCEC, LUAD, and STAD as cancer lineages where HMGN2P9 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HMGN2P9 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HMGN2P9 survival associations across molecular data types. HMGN2P9 RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HMGN2P9 RNA expression–survival associations across cancer types. High HMGN2P9 expression shows unfavorable associations in UCEC, BRCA, UCS, DLBC, CHOL and KIRC. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .003). Together, the overview and detailed table identify UCEC as the clearest survival context for HMGN2P9 RNA expression.
This table summarizes HMGN2P9 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for HMGN2P9. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HMGN2P9 shows higher tumor expression in LUAD. The LUAD box plot shows higher HMGN2P9 RNA expression in tumor versus normal tissue (log2 FC = +0.179, t-test p = .036).
This table shows molecular features associated with HMGN2P9 in patient tissues and cancer cell lines. In patient samples, HMGN2P9 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
